Neuropathic Pain Drug Market (Painful Diabetic Neuropathy, Postherpetic and Trigeminal Neuralgia) Forecast to 2022 in New Report Available at MarketOptimizer.org

Dallas, Texas (PRWEB) September 26, 2014 With seven promising neuropathic pain (NP) treatments expected to be launched in the coming years, the NP therapeutics market value – covering painful diabetic neuropathy, postherpetic neuralgia and trigeminal neuralgia – is forecast to increase from $ 2.58 billion in 2012 to $ 3.53 billion by 2022, at a […]

Byetta Lawsuit News: Bernstein Liebhard LLP Notes British Columbia’s Recent Decision to Discontinue Incretin Mimetic Drug Coverage from PharmaCare Program

New York, NY (PRWEB) August 15, 2014 Healthcare regulators in British Columbia have stopped patient coverage of a diabetes drug now involved in hundreds of Byetta lawsuits (http://www.byettalawsuit.com/) as well as several other medications, Bernstein Liebhard LLP reports. According to a notice posted earlier this month on Merck Canada’s website, the British Columbia Medical […]